On April 13, 2021, a joint statement from the CDC and FDA was released addressing 6 separate incidents of a rare form of blood clot which occurred in Johnson & Johnson vaccine recipients.
In all cases, the recipients were women and they ranged in ages 18-48. The statement explains that all the women were diagnosed with having a cerebral venous sinus thrombosis (CVST), a rare form of blood clot that does not respond positively to heparin (the typical drug used to treat blood clots).
One woman died and another is in critical condition.
The CDC plans to meet with the Advisory Committee on Immunization Practices (ACIP) on Wednesday to review the incidents, and the FDA will also investigate these cases.
The statement says, “we are recommending a pause in the use of this vaccine out of an abundance of caution.” and that, “This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.” (1)